Eloxxpharma
1 known investors
Eloxx Pharmaceuticals is a clinical-stage biotech developing exaluren, a ribosome-selective glycoside drug candidate that induces readthrough of premature stop codons caused by nonsense mutations to restore full-length functional proteins. It is investigating the therapy for rare genetically defined kidney diseases, specifically Alport syndrome and ADPKD, in patients with nonsense mutations.
BiotechLongevity
Investors Β· 1
Frequently asked questions
- What does Eloxxpharma do?
- Eloxx Pharmaceuticals is a clinical-stage biotech developing exaluren, a ribosome-selective glycoside drug candidate that induces readthrough of premature stop codons caused by nonsense mutations to restore full-length functional proteins. It is investigating the therapy for rare genetically defined kidney diseases, specifically Alport syndrome and ADPKD, in patients with nonsense mutations.
- Who are Eloxxpharma's investors?
- Eloxxpharma's investors include Pontifax Venture Capital.